Back close

Spectrum of Cutaneous Adverse Reactions to Levetiracetam and Human Leukocyte Antigen Typing in North-Indian Patients

Publication Type : Journal Article

Publisher : Korean Epilepsy Society

Source : Journal of Epilepsy Research

Url : https://doi.org/10.14581/jer.16016

Keywords : Human leukocyte antigen (HLA); Levetiracetam; Maculo-papular exanthem; Stevens-Johnson syndrome; Toxic Epidermal Necrolysis.

Campus : Faridabad

School : School of Medicine

Department : Dermatology

Year : 2016

Abstract : Background and purpose: Aromatic antiepileptic drugs are frequently implicated for cutaneous adverse drug reactions (cADRs); there are case-reports of even severe reactions like drug reaction eosinophilia and systemic symptoms (DRESS) and Stevens Johnson syndrome (SJS)-toxic epidermal necrolysis with Levetiracetam (LEV). Certain human leukocyte antigen (HLA)-alleles have strong association with cADRs due to specific drugs - HLA-B*15:02 and HLA-A*31:01 in Carbamazepine (CBZ)-related SJS in Han-Chinese and European populations, respectively. Here, the spectrum of cADRs to LEV was studied, and HLA-typing in patients with cADRs due to LEV and some who were LEV-tolerant was performed, in an attempt to find an association between HLA and such reactions. Methods: 589 patients taking LEV were screened for skin reactions, and eight patients with LEV-related cADRs and 25 LEV-tolerant controls were recruited - all 33 of North Indian ethnicity, their HLA-A, B, DRB1 genotyping done. Statistical analysis was done to compare carrier-rates and allele-frequencies of HLA-alleles between cases and controls (and healthy population, where necessary) for alleles occurring more than two times in either group. Results: Out of 589 patients on LEV screened, there were 8 cases of cADR: 5 with maculopapular exanthema (MPE), 2 of SJS, and 1 with DRESS. Although HLA-A*33:01 was seen to occur more in MPE cases as compared to tolerant controls, the difference was not statistically significant (odds ratio [OR] 6.00, 95% confidence interval [CI] 0.30-116.6; p = 0.31). HLA A*11:01 and 24:02 were found to occur more in LEV-tolerant controls than in cases (OR 0.23 [95% CI 0.02-2.36, p = 0.33] and 1.00 [95% CI 0.09-11.02, p = 1.00] respectively). Conclusions: Cutaneous reactions to LEV are very unusual, and their association with HLA in North-Indian population was not statistically significant.

Cite this Research Publication : Bhargavi Ramanujam, Kavish Ihtisham, Gurvinder Kaur, Shivani Srivastava, Narinder Kumar Mehra, Neena Khanna, Mahip Singh, Manjari Tripathi, Spectrum of Cutaneous Adverse Reactions to Levetiracetam and Human Leukocyte Antigen Typing in North-Indian Patients, Journal of Epilepsy Research, Korean Epilepsy Society, 2016, https://doi.org/10.14581/jer.16016

Admissions Apply Now